CSRxP Applauds Trump Administration’s Focus on Lowering Prescription Drug Prices

CSRxP Applauds Trump Administration’s
Focus on Lowering Prescription Drug Prices

Today CSRxP released the following statement from Executive Director John Rother, following Big Pharma’s meeting with President Trump at the White House:

“We applaud President Trump for making the out-of-control prices of prescription drugs a priority in his Administration.  Increased competition in the prescription drug market, real transparency into the drivers of drug prices, and ensuring that prices are linked to the value they provide are what will deliver lower prices for hardworking American families.  We look forward to working with Congress and the Administration to ensure that all patients are able to obtain lifesaving medications at prices they can afford.”